title: Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
authors.forename: Mariam B
authors.initials: MB
authors.lastname: Totonchy
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
authors.forename: Harib H
authors.initials: HH
authors.lastname: Ezaldein
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
authors.forename: Christine J
authors.initials: CJ
authors.lastname: Ko
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut2Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Jennifer N
authors.initials: JN
authors.lastname: Choi
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D001706:Biopsy; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D005831:Genital Diseases, Female / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013125:Spinal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D013203:Staphylococcal Infections / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C582435:pembrolizumab